Ayodele Ogunkoya

Ayodele Ogunkoya is a Group Leader of Bioconjugation at Catalent Biologics, a division of Catalent Pharma Solutions.1 He is based in Berkeley, California and has a background in pharmaceutical sciences, particularly in the field of antibody-drug conjugates (ADCs).13

Education and Qualifications

Ogunkoya holds a PhD in Ecology from Montana State University, which he completed between August 2015 and May 2020.2 Prior to his doctoral studies, he attended the University of Cape Town.2

Professional Experience

At Catalent Pharma Solutions, Ogunkoya leads a group focused on bioconjugation, which is a critical process in the development of targeted therapeutics like ADCs.1 His expertise in this area is evident from his participation in industry events, such as the World ADC London conference, where he has presented on the latest developments in ADC technology.3

Research and Expertise

Ogunkoya's work involves advanced pharmaceutical technologies, particularly in the realm of biologics and bioconjugation. This field is crucial for developing targeted therapies that can deliver drugs more precisely to diseased cells, potentially improving treatment efficacy while reducing side effects.3

Given his role and the nature of his work, Ayodele Ogunkoya is likely a key figure in Catalent's efforts to advance their capabilities in the production of complex biopharmaceuticals, especially in the rapidly evolving field of antibody-drug conjugates.